Diabetes

May 10, 2019

Revealing the anti-diabetic agent in the known anti-cancer agent Bexarotene: Bexarotene-based therapy for body weight control, energy homeostasis and TIIDM:Bexarotene inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 10/May/2019, 6.44 am

Introduction: What they say  A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator […]
May 8, 2019

Reversing Diabetes with blood pressure drug Verapamil: Verapamil [brand name: (Calan, Isoptin, Verelan)], a calcium channel blocker, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 8/May/2019, 8.19 am

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, […]
May 5, 2019

Yes to Autophagy, no to Diabetes: Mechanistic insights into how autophagy may ameliorate Diabetes Mellitus: Acute or intermittent autophagy  augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM, via upregulation of its target gene, 5/May/2019, 7.37 am

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection […]
May 5, 2019

Mechanistic insights into how Liraglutide may aid in the treatment of Diabetes: Liraglutide (brand name: Victoza, Saxenda, others), an acylated glucagon-like peptide-1 (GLP-1) agonist used in the treatment of Type II diabetes, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 5/May/2018, 7.09 am

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, the University of Alabama at […]